Soft glucocorticoid design: Structural elements and physicochemical parameters determining receptor-binding affinity

Pharmazie

Volumn 59, Issue 5, 2004, Pages 396-404

  Buchwald, P ^a   Bodor, Nicholas ^a  

^a IVAX Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETAMETHASONE; CORTICOSTEROID; CORTICOSTERONE; DEXAMETHASONE; ETIPREDNOL DICLOACETATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; LOTEPREDNOL ETABONATE; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; BINDING AFFINITY; CATARACT; CONFERENCE PAPER; CUSHINGOID SYNDROME; DRUG DESIGN; GLAUCOMA; GROWTH INHIBITION; HALOGENATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOGENICITY; LIPOPHILICITY; OSTEOPOROSIS; PHARMACOPHORE; PHYSICAL CHEMISTRY; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR BINDING; REGRESSION ANALYSIS; SKIN BRUISING;

ALGORITHMS; CHEMISTRY, PHYSICAL; DRUG DESIGN; GLUCOCORTICOIDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, GLUCOCORTICOID;

EID: 2642518935     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Baraniuk JN (1996) Molecular actions of glucocorticoids: an introduction. J Allergy Clin Immunol 97: 141-142.
2. Barnes PJ (2001) Molecular mechanisms of corticosteroids in allergic diseases. Allergy 56: 928-936.
3. Barnes PJ, Pedersen S, Busse WW (1998) Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157: S1-S53.
4. Barton P, Laws AP, Page MI (1994) Structure-activity relationships in the esterase-catalysed hydrolysis and transesterification of esters and lactones. J Chem Soc Perkin Trans 2: 2021-2029.
5. Bledsoe RK, Montana VG, Stanley TB, et al. (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110: 93-105.
6. Bodor N (1984) Soft drugs: principles and methods for the design of safe drugs. Med Res Rev 3: 449-469.
7. Bodor N (1988) The application of soft drug approaches to the design of safer corticosteroids. In: Christophers E, Kligman AM, Schöpf E, Stoughton RB (eds), Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs. New York: Raven Press Ltd., p 13-25.
8. Bodor N (1989) Designing safer ophthalmic drugs. In: van der Goot H, Domány G, Pallos L, Timmerman H (eds), Trends in Medicinal Chemistry '88 Proceeding of the Xth International Symposium on Medicinal Chemistry. Amsterdam: Elsevier, p 145-164.
9. Bodor N (1991) Soft steroids having anti-inflammatory activity. U.S. Patent 4,996,335.
10. Bodor N (1993) Design of novel soft corticosteroids. In: Korting HC, Maibach HI (eds), Topical Glucocorticoids with Increased Benefit/Risk Ratio. Basel: Karger, p 11-19.
11. Bodor N (1996) Design of biologically safer chemicals based on retrometabolic concepts. In: DeVito SC, Garrett RL (eds), Designing Safer Chemicals. Green Chemistry for Pollution Prevention, Vol 640. Washington DC: ACS, p 84-115.
12. Bodor N (1999) Androstene derivatives. U.S. Patent 5,981,517.
13. Bodor N, Buchwald P (1997) Molecular size based approach to estimate partition properties for organic solutes. J Phys Chem B 101: 3404-3412.
14. Bodor N, Buchwald P (2000) Soft drug design: general principles and recent applications. Med Res Rev 20: 58-101.
15. Bodor N, Buchwald P (2002) Design and development of a soft corticosteroid, loteprednol etabonate. In: Schleimer RP, O'Byrne PM, Szefler SJ, Brattsand R (eds), Inhaled Steroids in Asthma. Optimizing Effects in the Airways. New York: Marcel Dekker, p 541-564.
16. Bodor N, Buchwald P (2003) Retrometabolism-based drug design and targeting. In: Abraham DJ (ed), Burger's Medicinal Chemistry and Drug Discovery. Vol. 2, Drug Discovery and Drug Development, 6th Edition, 6th ed, Vol 2. New York: Wiley, p 533-608.
17. Bodor N, Harget AJ, Philips EW (1983) Structure-activity relationships in the antiinflammatory steroids: A pattern-recognition approach. J Med Chem 26: 318-328.
18. Buchwald P (2000) Modeling liquid properties, solvation, and hydrophobicity: a molecular size-based perspective. Perspect Drug Disc Des 19: 19-45.
19. Buchwald P, Bodor N (1998) Octanol-water partition: Searching for predictive models. Curr Med Chem 5: 353-380.
20. Derendorf H, Hochhaus G, Meibohm B, Möllmann H, Barth J (1998) Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J. Allergy Clin Immunol 101: S440-S446.
21. Druzgala P, Bodor N (1991) Regioselective O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17α-alkoxy, a 17α-(1′-alkoxyethyloxy), a 17α-alkoxymethyloxy, or a 17α-methylthiomethyloxy function. Steroids 56: 490-494.
22. Druzgala P, Hochhaus G, Bodor N (1991) Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem 38: 149-154.
23. Hochhaus G, Druzgala P, Hochhaus R, Huang M-J, Bodor N (1991) Glucocorticoid activity and structure activity relationship in a series of some novel 17α-ether-substituted steroids: influence of 17α-substituents. Drug Design Deliv 8: 117-125.
24. Kelly HW (1998) Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 102: S36-S51.
25. Kumar R, Thompson EB (1999) The structure of the nuclear hormone receptors. Steroids 64: 310-319.
26. Kurucz I, Tóth S, Németh K, et al. (2003) Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166). J Pharmacol Exp Ther 307: 83-92.
27. Le Fanu J (1999) The Rise and Fall of Modern Medicine. New York: Carrol & Graf.
28. Mager DE, Moledina N, Jusko WJ (2003) Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci 92: 1521-1525.
29. Martindale W (1996) The Extra Pharmacopoeia, 31st ed. London: Pharmaceutical Press.
30. Miklós A, Magyar Z, Kiss É, et al. (2002) 28-Day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period. Pharmazie 57: 142-146.
31. Monder C, Bradlow HL (1980) Cortoic acids: explorations at the frontier of corticosteroid metabolism. Recent Progr Horm Res 36: 345-400.
32. Muller M, Renkawitz R (1991) The glucocorticoid receptor. Biochim Biophys Acta 1088: 171-182.
33. Noble S, Goa KL (1998) Loteprednol etabonate. Clinical potential in the management of ocular inflammation. BioDrugs 10: 329-339.
34. Rohatagi S, Arya V, Zech K, et al. (2003) Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43: 365-378.
35. Rohdewald PJ (1998) Comparison of clinical efficacy of inhaled glucocorticoids. Arzneim.-Forsch./Drug Res 48: 789-796.
36. Schimmer BP, Parker KL (1996) Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE (eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, p 1459-1485.
37. Seeley DH, Wang WY, Salhanick HA (1982) Molecular interactions of progesterone analogues with rabbit uterine cytoplasmic receptor. J Biol Chem 257: 13359-13366.